Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms

Qi Zhang, Qi Han, Jie Zi, Jinlong Ma, Huihui Song, Yulu Tian, Mary McGrath, Chunhua Song, Zheng Ge

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


EZH2 is a component of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. EZH2 mutations are associated with oncogenesis and progression of cancers. However, the relationship between the clinical outcome of patients with myeloid malignancies and EZH2 mutations is controversial. Therefore, we performed a meta-analysis of 8 studies (n = 2243 patients) that evaluates the correlation between EZH2 mutations and overall survival (OS) in patients with myeloid neoplasms. EZH2 mutations were associated with significantly worse OS (hazard ratio [HR] = 2.37, 95% confidential interval (CI), 1.48–3.79). In a word, EZH2 mutations indicate a poor prognosis for patients with myeloid neoplasms.

Original languageEnglish (US)
Pages (from-to)276-281
Number of pages6
JournalGenes and Diseases
Issue number3
StatePublished - Sep 2019

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Genetics(clinical)
  • Cell Biology


Dive into the research topics of 'Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms'. Together they form a unique fingerprint.

Cite this